micro-community-banner
 
  • Saved

3yr
Treatment of Richter's Syndrome - PubMed

Treatment of Richter's Syndrome - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/29159711/

Based on the available literature, mostly derived from retrospective or non-randomized phase I or II studies, it is difficult to define an optimized treatment approach for patients developing Richter's syndrome...


Conclusions: The noncovalent Bruton's tyrosine kinase inhibitor pirtobrutinib has achieved responses in approximately two-thirds of heavily pretreated patients and, given its favorable toxicity profile, appears ideally suited to combining with other active agents. Finally, we review available data for bispecific antibodies, antibody-drug...

  • Saved

3yr

Paper: Efficacy of Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Relapsed / Refractory Waldenström Macroglobulinemia: Results from the Phase 1/2 BRUIN Study

Source : https://ash.confex.com/ash/2022/webprogram/Paper159123.html

Oral and Poster Abstracts Oral 623. Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological III Research, clinical trials, Biological therapies, adult, Lymphomas, non-Hodgkin lymphoma, Clinical Research,...


Conclusions: In this cohort of heavily pretreated R/R WM pts, pirtobrutinib was highly active, regardless of the pattern of prior therapy. The depth of response observed, as demonstrated by the favorable VGPR rate, is noteworthy in the subset of pts with prior covalent BTKi therapy. Pirtobrutinib was well-tolerated with low-rates of...

  • Saved

3yr
Highlights from The American Society of Hematology Annual Meeting and Exposition

The four-day conference, also broadcast virtually, brought together more than 30,000 hematology professionals from every subspecialty to learn from one another, potentially change clinical practice, and save more lives.

Above, we summarize some of the presentations that caught our attention at the conference. Click to access.

  • Saved

3yr
The 64th American Society of Hematology Annual Meeting and Exposition

Considered the premier event in malignant and nonmalignant hematology, the 64th American Society of Hematology (ASH) Annual Meeting and Exposition is taking place in New Orleans from Dec. 10 to 13, 2022.

Click above to access summaries of presentations that caught our eye so far.

  • Saved

3yr
Role of Artificial Intelligence and Machine Learning in Prediction, Diagnosis, and Prognosis of Cancer

Role of Artificial Intelligence and Machine Learning in Prediction, Diagnosis, and Prognosis of Cancer

Source : https://www.cureus.com/articles/116355-role-of-artificial-intelligence-and-machine-learning-in-prediction-diagnosis-and-prognosis-of-cancer

Cancer is one of the most devastating, fatal, dangerous, and unpredictable ailments. To reduce the risk of fatality in this disease, we need some ways to predict the disease, diagnose...



Conclusions: Both solid and non-solid tumors can be diagnosed precisely with the help of AI and ML algorithms. The prognosis of the disease can also be forecasted with AI and its approaches like deep learning. This improvement in cancer care is a turning point in advanced healthcare and will deeply impact patient’s life for good.